SERB Pharmaceuticals
SERB Pharmaceuticals is a global pharmaceutical company dedicated to treating complex and life-threatening conditions, supporting clinicians, healthcare systems, and governments. With over 30 years of experience, they focus on emergency care and rare diseases, offering a broad portfolio of medicines, antidotes, and medical countermeasures. Their mission is to improve patients' quality of life and offer hope through innovative and high-quality medicines, with a strong emphasis on responsibility, integrity, and patient-first values.
Industries
Nr. of Employees
large (251-1000)
SERB Pharmaceuticals
Products
Ovine-derived Fab fragment antivenom for North American pit viper envenomation
Sheep-derived antibody fragment antivenom indicated for management of crotalid (pit viper) envenomation; produced from antibodies generated against venom proteins from multiple representative snake species and affinity-purified before blending.
Glucarpidase enzyme antidote for high-dose methotrexate toxicity
Enzymatic antidote used to rapidly lower plasma methotrexate concentrations and mitigate kidney injury from high-dose methotrexate therapy.
Iloprost injection for severe frostbite
Vasodilator intravenous formulation indicated to reduce risk of digit amputation in severe frostbite by improving microvascular perfusion.
Digoxin immune Fab (ovine) for digoxin toxicity
Ovine-derived immune Fab indicated as an antidote for life-threatening digoxin toxicity and severe digoxin overdose.
Collatamp G
Collatamp G is a surgical antibiotic collagen implant designed for infection management.
Danyelza
Danyelza is an anti-GD2 monoclonal antibody developed for the treatment of high-risk neuroblastoma.
Ovine-derived Fab fragment antivenom for North American pit viper envenomation
Sheep-derived antibody fragment antivenom indicated for management of crotalid (pit viper) envenomation; produced from antibodies generated against venom proteins from multiple representative snake species and affinity-purified before blending.
Glucarpidase enzyme antidote for high-dose methotrexate toxicity
Enzymatic antidote used to rapidly lower plasma methotrexate concentrations and mitigate kidney injury from high-dose methotrexate therapy.
Iloprost injection for severe frostbite
Vasodilator intravenous formulation indicated to reduce risk of digit amputation in severe frostbite by improving microvascular perfusion.
Digoxin immune Fab (ovine) for digoxin toxicity
Ovine-derived immune Fab indicated as an antidote for life-threatening digoxin toxicity and severe digoxin overdose.
Collatamp G
Collatamp G is a surgical antibiotic collagen implant designed for infection management.
Danyelza
Danyelza is an anti-GD2 monoclonal antibody developed for the treatment of high-risk neuroblastoma.
Services
Manufacture and oversight of polyclonal antibody and biologic production using a hybrid model combining internal facilities and external contract manufacturers.
Direct sales teams in key territories with a network of distribution partners to supply specialist medicines and medical countermeasures internationally.
In-house regulatory and quality teams providing product registration, compliance, and regulatory strategy support for lifecycle and market entry activities.
24/7 medical information hotline and structured adverse event reporting and pharmacovigilance activities to monitor product safety post-launch.
Research programs focused on antibody-based antidotes and therapies, including preclinical studies, animal study governance and clinical development.
Evaluation and execution of acquisitions, licensing deals and portfolio integrations to expand product offerings in critical care and rare diseases.
Manufacture and oversight of polyclonal antibody and biologic production using a hybrid model combining internal facilities and external contract manufacturers.
Direct sales teams in key territories with a network of distribution partners to supply specialist medicines and medical countermeasures internationally.
In-house regulatory and quality teams providing product registration, compliance, and regulatory strategy support for lifecycle and market entry activities.
24/7 medical information hotline and structured adverse event reporting and pharmacovigilance activities to monitor product safety post-launch.
Research programs focused on antibody-based antidotes and therapies, including preclinical studies, animal study governance and clinical development.
Evaluation and execution of acquisitions, licensing deals and portfolio integrations to expand product offerings in critical care and rare diseases.
Expertise Areas
- Antidote and antivenom development
- Biologics and polyclonal antibody manufacturing
- Clinical development and trial execution
- Pharmacovigilance and medical information
Key Technologies
- Polyclonal antibody production
- Affinity purification of antibodies
- Venom-derived immunogen preparation
- Antibody platform development
News & Updates
The Phase 3 trial achieved primary endpoint, restoring platelet function in patients undergoing urgent surgery or experiencing major bleeding.
A comprehensive study demonstrating Voraxaze®'s effectiveness in treating MTX-AKI.
Aurlumyn™ (iloprost) Injection, the first FDA-approved treatment for severe frostbite, is now commercially available.
Expanded emergency care portfolio with new treatment for severe frostbite.
Strengthened medical countermeasures portfolio.
Broadened portfolio with new medicines for rare diseases.
The Phase 3 trial achieved primary endpoint, restoring platelet function in patients undergoing urgent surgery or experiencing major bleeding.
A comprehensive study demonstrating Voraxaze®'s effectiveness in treating MTX-AKI.
Aurlumyn™ (iloprost) Injection, the first FDA-approved treatment for severe frostbite, is now commercially available.
Expanded emergency care portfolio with new treatment for severe frostbite.
Strengthened medical countermeasures portfolio.
Broadened portfolio with new medicines for rare diseases.